Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patient Education and Antidepressant Response to Propofol Sedation (SAGE)
NCT06705270Not yet recruiting
- Sponsor
- Stanford University
- Start
- Sep 2026
- Primary completion
- Sep 2028
01
Overview
Randomised trial of naloxone in major depressive disorder (MDD) (4 arms), sponsored by Stanford University. Primary endpoint: Change in clinician-rated depression severity at 3 days. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
naloxone
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06705270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06705270.